- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Efficacy and Safety of Levetiracetam as Mono and Add on Therapy in Treatment of Epilepsy | ||
| Kerbala Journal of Medicine | ||
| Article 1, Volume 10, Issue 2, 2017, Pages 2709-2713 PDF (0 K) | ||
| Authors | ||
| Sarwer Jamal Al- Bajalan; Mohammed Tahir Kurmanji; Murad W. Kamil | ||
| Abstract | ||
| background: Epilepsy is the second most common chronic neurological disorder after migraine affecting 2% of population with a high incidence of failure to achieve seizure freedom with the usual antiepileptic drugs. Levetiracetam (LEV) is an antiepileptic drug with less drug interactions, minimal side effects, a favorable pharmacokinetic profile and a wide spectrum of anticonvulsant effects in animal models for different types of epileptic seizures. Objectives: To define the efficacy and safety of LEV in the treatment of epilepsy as add on or monotherapy. Patients and methods: A random sample of 52 patients with epilepsy, evaluated in a descriptive cross-sectional study for the efficacy and safety of LEV in epilepsy, they were collected among epileptic patients attending the Neurology consultation Clinic in Sulaimani city in the Iraqi Kurdistan Region from May 2012 to May 2013. All the patients were interviewed by using questionnaire forms with comprehensive history, clinical examination, radiological, EEG and laboratory studies done to all patients. Results: The sample involved female patients 2 folds more than males. Mean patients age was 24.54 ± 13.9 years. Mean duration of treatment; 2.7 years. Mean LEV dosage: 1457 ± 682 mg / day. Seventeen patients received monotherapy and 35 patients received add on therapy. Mean Seizure frequency was 44 attacks / month before treatment and 4 after treatment. Mean percent of seizure reduction was 95.1% in mono therapy and 91.46% in add on therapy. Conclusion: LEV is a safe, effective, broad spectrum antiepileptic drug that could be used as monotherapy or add on therapy in the treatment of generalized and focal epilepsy. | ||
| Keywords | ||
| Levetiracetam; epilepsy; Add on therapy | ||
|
Statistics Article View: 161 PDF Download: 84 |
||